Joining VeloClub not only supports the work we do, there are some fantastic benefits:
by Mark Zalewski
June 2, 2016
In today’s CT Daily News Digest: Rajablou wins climbing stage, Shorabi takes lead in Tour of Japan; Drucker wins Tour of Luxembourg prologue; After a promising Giro d’Italia, Joe Dombrowski’s stock is on the rise. Is a move in store?; Boonen suggests more motorcycles would increase safety; Simon Yates on Dauphine start list; Tour de Suisse to show rider data in real-time; Dutch name men’s squad for Rio road race; Boardman on Sutton: ‘Victim of lynch mob’; Australia’s only female CX national champ retires; US State Department issues travel alert around Tour de France; Riding the Rocacorba with David Millar; Motorist pulls weapon on cyclist in road rage incident.
Orica-GreenEdge’s Simon Yates is on the team’s start list for the Criterium du Dauphine, beginning Sunday. The 23-year-old British rider tested positive for the asthma drug terbutaline at Paris-Nice in March.
Though he has not raced since early April, he is allowed to race since terbutaline is designated as a specified substance by the UCI and does not require a provisional suspension while awaiting further testing and investigation.
Some riders do stop racing after notification of an adverse analytical finding, either voluntarily or by mandate from their team. As well, any sanction that is handed down begins from when the athlete last competed.
The Orica-GreenEdge team blamed the positive sample on their team doctor’s oversight in applying for a Therapeutic Use Exemption (TUE). TUEs allow athletes with real medical needs to use substances that would otherwise be prohibited.
The team said it would submit all “documentation, statements and evidence in order to clarify everything.”
Click through to read more at Sky Sports.